Advances in Cellular Immunotherapy for Hematological Malignancies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 230
Special Issue Editor
Special Issue Information
Dear Colleagues,
Adoptive cellular immunotherapies, particularly chimeric antigen receptor T-cells (CAR-T cells), have achieved great clinical success in the treatment of hematologic malignancies and show tremendous potential for cancer therapy. However, numerous caveats such as an immunosuppressive tumor microenvironment, impaired T cell metabolism and exhaustion, absence or loss of targets, and autologous CAR-T products with variable therapeutic efficacy currently limit effective and sustainable CAR-T cell therapy. Since CAR-redirected natural killer (NK) cells or NK-cells genetically engineered to express a functional T-cell receptor have demonstrated convincing therapeutic efficacy in preclinical and initial clinical studies, these cells represent promising alternative effectors for cellular immunotherapy. Similarly, numerous anti-tumor responses observed with genetically engineered invariant NKT cells suggest that redirected NKT cells may be of great therapeutic interest. Finally, improved bispecific T-cell or NK-cell engager formats are tested in clinical studies and are valuable candidates for complementing current immunotherapeutic strategies. Building on recent breakthrough findings and developments, this Special Issue will focus on advances to improve cellular immunotherapy of hematologic malignancies and invites researchers and experts in the field to contribute selected preclinical or clinical data on this exciting topic.
Dr. Udo F. Hartwig
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cellular immunity
- T cell and NK cell immunology
- oncoimmunology
- cellular immunotherapy
- cellular therapies to hematological malignancies
- T cell and NK cell engineering
- CAR T and NK cell therapy
- bispecific T and NK cell antibodies
